Construction and Preliminary Evaluation of Dyadic Acceptance and Commitment Therapy for Couples With Fear of Lung Cancer Recurrence

May 15, 2026 updated by: Feifei Huang

The goal of this clinical trial is to develop a simple, scientific, effective, and culturally adapted dyadic Acceptance and Commitment Therapy (ACT) intervention program (the ADAPT program) targeting fear of cancer recurrence (FCR) among lung cancer patients and their spouse caregivers. The study will also evaluate the feasibility, acceptability, and preliminary effectiveness of the ADAPT program.

The main research questions are as follows:

  • Is the ADAPT intervention program feasible and acceptable for lung cancer patients and their spouse caregivers?
  • Compared with usual care, can the ADAPT intervention program preliminarily reduce FCR levels in both patients and their spouse caregivers? Can the program improve coping styles, illness perceptions, family functioning, and intimate relationships among both patients and their spouse caregivers? Can the program enhance psychological flexibility and quality of life (QOL) in both patients and their spouse caregivers? Researchers will compare the ADAPT intervention program with usual care to evaluate its preliminary effectiveness in reducing FCR among lung cancer patients and their spouse caregivers.

Participants will:

  • Receive the ADAPT intervention twice during each radiotherapy and/or chemotherapy cycle, for a total of three treatment cycles (approximately 3 months);
  • Complete questionnaires at baseline (before the intervention), immediately after the intervention, and one month post-intervention;
  • Report outcomes including FCR severity, FCR triggers, psychological flexibility, illness perception, dyadic coping, family functioning, intimacy, and quality of life (QOL).

Study Overview

Study Type

Interventional

Enrollment (Estimated)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Feifei Huang, Ph. D
  • Phone Number: +86 13763869099
  • Email: pt860315@163.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

Patients:

  • Diagnosis of primary lung cancer confirmed by pathological examination.
  • Age ≥ 22 years for men and ≥ 20 years for women (legal marriage age in China).
  • Have undergone lung cancer surgery and are scheduled to receive the first round of radiotherapy and/or chemotherapy treatment
  • Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) score ≥ 13, indicating moderate-to-severe FCR.
  • Eastern Cooperative Oncology Group (ECOG) ≤2.
  • Aware of their diagnosis and willing to participate voluntarily.
  • Normal cognitive function (Montreal Cognitive Assessment [MoCA] score ≥ 26), alert and conscious, and able and willing to communicate their thoughts.

Spouse Caregivers:

  • Identified by the patient as the primary caregiver, providing ≥ 50% of care in the past 2 weeks.
  • Legally married to the patient.
  • Age ≥ 22 years for men and ≥ 20 years for women.
  • Normal cognitive function (MoCA score ≥ 26), no diagnosed mental disorders, able to communicate effectively, and willing to share their thoughts.

Exclusion Criteria

Patients:

  • Diagnosed mental disorders or currently receiving psychiatric treatment.
  • Presence of personality disorders, intellectual disability, memory disorders, brain injury, or neurological disease.
  • Concurrent malignant tumors in other organs.
  • Severe complications (e.g., chest pain and/or dyspnea due to pleural tumor invasion).
  • Spouse caregiver unwilling to participate.
  • History of upper limb fractures or surgery resulting in impaired hand function.
  • Participation in other similar psychological interventions.

Spouse Caregivers:

  • Presence of serious comorbid conditions (e.g., respiratory failure, malignant tumors, or other critical illnesses).
  • Patient unwilling to participate.
  • Participation in other research studies.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group

In addition to routine care provided to the control group, the ACT intervention will be delivered by researchers who have completed formal training in Acceptance and Commitment Therapy (ACT). The intervention will be conducted in a quiet and comfortable demonstration room within the department.

The intervention will be delivered in a face-to-face, couple-based format. It will consist of six sessions, with two sessions per treatment cycle, each lasting 35-75 minutes, over a total of three treatment cycles.

The intervention will incorporate techniques such as metaphor-based exercises, mindful breathing, body scan, the T-puzzle, and the Chinese finger trap.

The preliminary structure is as follows: six fixed in-person sessions (Sessions 1-6), supplemented by online homework assignments completed between sessions.

Active Comparator: Control group

① Health education:

  1. Disease knowledge education
  2. Nutrition and hygiene education

    • Follow-up management and symptom monitoring: Conduct a telephone follow-up within one month after the patient is discharged from the hospital to ensure timely monitoring of the patient's physical condition.

      • Home rehabilitation management: Provide nutritional counseling services for the patient and spouse caregiver, guide home-based dietary adjustments, and maintain good nutritional status and immunity. Encourage the patient and spouse caregiver to communicate promptly with the medical team when experiencing uncomfortable symptoms, thereby speeding up recovery and improving rehabilitation outcomes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in fear of cancer recurrence severity of lung cancer patients-The Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The scale consists of 9 items, each rated from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 36, where 0 indicates no fear of cancer recurrence and 36 indicates the highest possible fear. A score of 13 or higher is defined as subclinical fear of cancer recurrence.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in fear of cancer recurrence severity of spouse caregivers-Fear of Cancer Recurrence Inventory Short Form-Caregiver Version (FCRI-SF-C)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The scale consists of 9 items, each rated from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 36, where 0 indicates no fear of cancer recurrence and 36 indicates the highest possible fear. A score of 13 or higher is defined as subclinical fear of cancer recurrence.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recruitment Rate: Percentage of Eligible Participants Who Successfully Enroll in the Study Out of All Potentially Eligible Participants Meeting Inclusion/Exclusion Criteria
Time Frame: Post-intervention (3 months)
Recruitment rate is calculated as (number of eligible participants who successfully enroll in the study / total number of potentially eligible participants meeting all inclusion and none of the exclusion criteria) × 100%. The rate ranges from 0% to 100%, with a higher rate indicating better recruitment efficiency.
Post-intervention (3 months)
Consent Compliance Rate: Percentage of Participants Who Sign Informed Consent Among Those Who Meet Inclusion Criteria
Time Frame: Post-intervention (3 months)
Consent compliance rate is calculated as (number of participants who sign the informed consent form / total number of participants who meet the predefined inclusion criteria) × 100%. The rate ranges from 0% to 100%.
Post-intervention (3 months)
Participation Rate: Percentage of Randomized Participants Who Completed All Intervention Sessions
Time Frame: Post-intervention (3 months)
Participation rate is calculated as (number of participants who completed all intervention sessions / total number of participants randomized) × 100%. The rate ranges from 0% to 100%.
Post-intervention (3 months)
Withdrawal Rate: Percentage of Initially Enrolled Participants Who Voluntarily Withdraw or Are Lost to Follow-Up
Time Frame: Post-intervention (3 months)
Withdrawal rate is calculated as (number of participants who voluntarily withdraw from the study or are lost to follow-up after enrollment / total number of participants initially enrolled) × 100%. The rate ranges from 0% to 100%.
Post-intervention (3 months)
Number of Participants with Study-Related Adverse Events as Assessed by CTCAE v4.0
Time Frame: Intervene in the whole process (3 months)
The study uses a self-developed Adverse Event Form to document study-related adverse events (AEs) occurring during the study period. The incidence rate is calculated as (number of participants experiencing at least one study-related AE / total number of enrolled participants) × 100%. Severity grading follows the CTCAE v4.0.
Intervene in the whole process (3 months)
Satisfaction with the Intervention Program as Assessed by Qualitative Interviews
Time Frame: Post-intervention (3 months)
Semi-structured interviews are conducted by the investigator using a final interview guide developed through group brainstorming and revised by a nursing professor experienced in qualitative research. Sampling continues until no new themes emerge and meaning saturation is achieved. Thematic analysis is used to identify satisfaction-related patterns, and findings are reported with representative quotes. No predefined numeric threshold is applied.
Post-intervention (3 months)
Change from baseline in fear of cancer recurrence triggering factors-The Fear of Cancer Recurrence Inventory-Triggering factors (FCRI-T)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
This 8-item dimension assesses how often daily triggers elicit fear of cancer recurrence. Each item is scored from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 32, where 0 indicates that none of the factors trigger fear and 32 indicates that all factors always trigger fear.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in psychological flexibility-Comprehensive Assessment of ACT Processes (CompACT)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The CompACT contains 22 items, each scored from 0 to 6. Zero is equivalent to "never" and 6 indicates "always". After reverse-scoring the values and committed action domain (plus four items of the mindfulness and self-as-context domain), total scores range from 0 to 132, where 0 indicates the lowest possible psychological flexibility and 132 indicates the highest possible psychological flexibility.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in illness perception-Brief Illness Perception Questionnaire (B-IPQ)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The B-IPQ includes 8 items, each scored from 0 to 10. Zero is equivalent to "no perception of that aspect" and 10 indicates "extreme perception of that aspect". Total scores range from 0 to 80, where 0 indicates a very benign illness perception and 80 indicates the most threatening illness perception possible. The ninth open-ended item asks participants to list the three most important causal factors.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in dyadic coping-Dyadic Coping Inventory (DCI)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The DCI consists of 37 items, each rated from 1 to 5. One is equivalent to "very rarely" and 5 indicates "very frequently". Total scores range from 35 to 75, where 35 indicates the lowest possible dyadic coping competence and 75 indicates the highest possible dyadic coping competence.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in intimate relationship-Unidimensional Relationship Closeness Scale (URCS)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
This 11-item scale uses a 5-point scale from 1 to 5. 1 is equivalent to "strongly disagree" and 5 indicates "strongly agree". The mean of all item scores is calculated, ranging from 1 to 5, where 1 indicates the lowest perceived closeness and 5 indicates the highest perceived closeness.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in family care-Family Adaptation, Partnership, Growth, Affection, Resolve index Questionnaire (Family APGAR Questionnaire)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The Family APGAR has 5 items, each scored from 0 to 2. Zero is equivalent to "hardly ever" and 2 indicates "almost always". Total scores range from 0 to 10, where 0 indicates the poorest family function and 10 indicates the best family function. Scores of 7-10 indicate good family function, 4-6 moderate dysfunction, and 0-3 severe dysfunction.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in quality of life of lung cancer patients-Functional Assessment of Cancer Therapy (FACT-L V4.0)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The FACT-L V4.0 consists of 36 items. Each item is scored from 0 to 4. Zero is equivalent to "not at all" and 4 indicates "very much". Positively worded items are scored 0-4; reverse-worded items are scored 4-0. The total score is the sum of five dimension scores (physical, social/family, emotional, functional, and lung-specific), ranging from 0 to 144, where 0 indicates the poorest possible quality of life and 144 indicates the best possible quality of life.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in quality of life of spouse caregivers-The 12-item short from healthy survey (SF-12)
Time Frame: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The SF-12 includes 12 items covering eight dimensions. Items 1,8,9,10 are reverse-scored. Standardized scores for the PCS and MCS each range from 0 to 100, where 0 indicates the worst possible quality of life and 100 indicates the best possible quality of life.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Feifei Huang, Ph. D, Fujian Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 15, 2026

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

May 4, 2026

First Submitted That Met QC Criteria

May 10, 2026

First Posted (Actual)

May 14, 2026

Study Record Updates

Last Update Posted (Actual)

May 19, 2026

Last Update Submitted That Met QC Criteria

May 15, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Ethical Review No. 2 (2026)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The datasets are not publicly available due privacy reasons but are available from the director upon reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Neoplasms

Clinical Trials on routine care

Subscribe